# Jennifer A. Chan

Source: https://onco.cc/people/jennifer-chan/  
OnCo record `jennifer-chan` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Boston oncologist who led CABINET, the trial that showed cabozantinib delays progression of advanced neuroendocrine tumours after other treatments have failed.

## Summary

Jennifer Chan directs the neuroendocrine and carcinoid tumour programme at Dana-Farber Cancer Institute. She was the study chair and first author of the 2024 New England Journal of Medicine report of the Alliance CABINET trial, in which cabozantinib improved progression-free survival compared with placebo in previously treated advanced pancreatic and extra-pancreatic neuroendocrine tumours, supporting its approval in both groups.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: neuroendocrine; targeted-therapy; trialist
- Role: Clinical Director, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute
- Specialisms: Neuroendocrine tumours; Targeted therapy; Cooperative-group trials

## Connected records

- cancers: [Lung neuroendocrine tumours (typical and atypical carcinoid)](https://onco.cc/cancers/lung-net/), [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/), [Pancreatic neuroendocrine tumours](https://onco.cc/cancers/pancreatic-net/), [Small intestinal neuroendocrine tumours](https://onco.cc/cancers/small-intestinal-net/)
- institutions: [Dana-Farber Brigham Cancer Center](https://onco.cc/institutions/dana-farber/)
- key papers: [CABINET (Alliance A021602): cabozantinib for advanced neuroendocrine tumours](https://onco.cc/key-papers/paper-cabinet-cabozantinib-nejm-2024/)

---
JSON: https://onco.cc/api/v1/entities/jennifer-chan.json